Freeze dried cryoprecipitate: a clinical evaluation.
Freeze dried cryoprecipitate was used in the treatment of 14 patients with haemophilia A. The in vivo recovery was 91.2% which is comparable to that reported from other parts of Europe. The product was efficacious and no adverse effects were reported. Freeze dried cryoprecipitate is the high yield product of a low technology process and as such may be of value in reducing any possible shortfall in the factor VIII requirements of the haemophiliac population of the UK.
D011232:Chemical Precipitation; D003080:Cold Temperature; D005069:Evaluation Studies as Topic; D005169:Factor VIII / Q000600:supply & distribution / Q000627:therapeutic use*; D005612:Freeze Drying; D006467:Hemophilia A / Q000628:therapy*; D006801:Humans; D006113:United Kingdom
D005169:Factor VIII